CO6630162A2 - Derivados del ácido 1-amino -2-ciclopropiletilboronico - Google Patents

Derivados del ácido 1-amino -2-ciclopropiletilboronico

Info

Publication number
CO6630162A2
CO6630162A2 CO12195461A CO12195461A CO6630162A2 CO 6630162 A2 CO6630162 A2 CO 6630162A2 CO 12195461 A CO12195461 A CO 12195461A CO 12195461 A CO12195461 A CO 12195461A CO 6630162 A2 CO6630162 A2 CO 6630162A2
Authority
CO
Colombia
Prior art keywords
cyclopropylethylboronic
amino
acid derivatives
compositions
treatment
Prior art date
Application number
CO12195461A
Other languages
English (en)
Inventor
Paul Fleming
Jing Li
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6630162(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CO6630162A2 publication Critical patent/CO6630162A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona nuevos compuestos útiles como inhibidores de proteasoma. La invención también proporciona composiciones farmacéuticas que comprenden los compuestos de la invención y métodos para usar las composiciones en el tratamiento de diferentes enfermedades.
CO12195461A 2010-03-31 2012-10-30 Derivados del ácido 1-amino -2-ciclopropiletilboronico CO6630162A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31

Publications (1)

Publication Number Publication Date
CO6630162A2 true CO6630162A2 (es) 2013-03-01

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12195461A CO6630162A2 (es) 2010-03-31 2012-10-30 Derivados del ácido 1-amino -2-ciclopropiletilboronico

Country Status (25)

Country Link
US (3) US8513218B2 (es)
EP (1) EP2552216B1 (es)
JP (1) JP5933523B2 (es)
KR (1) KR20130036228A (es)
CN (3) CN102892291A (es)
AR (1) AR080863A1 (es)
AU (1) AU2011235227B2 (es)
CA (1) CA2794334C (es)
CL (1) CL2012002733A1 (es)
CO (1) CO6630162A2 (es)
CR (1) CR20120529A (es)
DO (1) DOP2012000257A (es)
EA (1) EA029521B1 (es)
EC (1) ECSP12012249A (es)
MA (1) MA34169B1 (es)
MX (1) MX2012011298A (es)
NZ (1) NZ602622A (es)
PE (1) PE20130383A1 (es)
RU (1) RU2012146101A (es)
SG (1) SG184222A1 (es)
TN (1) TN2012000465A1 (es)
UA (1) UA110612C2 (es)
UY (1) UY33314A (es)
WO (1) WO2011123502A1 (es)
ZA (2) ZA201207406B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CN101506224B (zh) 2006-06-19 2016-03-30 欧尼斯治疗公司 蛋白酶体抑制用的肽环氧酮
SG10201902704TA (en) 2007-10-04 2019-04-29 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
WO2009154737A1 (en) 2008-06-17 2009-12-23 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
ME01133B (me) 2008-10-21 2013-03-20 Onyx Therapeutics Inc Kombinovana terapija sa peptidnim epoksiketonima
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
PE20130383A1 (es) 2010-03-31 2013-04-24 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico
AU2011289615B2 (en) 2010-08-10 2015-05-07 Melinta Therapeutics, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013071142A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013071163A2 (en) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CN104204797B (zh) 2012-01-24 2017-05-31 米伦纽姆医药公司 治疗癌症的方法
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
CN109096370B (zh) * 2012-07-26 2022-03-18 圣特莱国际公司 多肽环氧酮化合物
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN105705149A (zh) 2013-10-03 2016-06-22 米伦纽姆医药公司 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法
USRE49816E1 (en) 2014-01-10 2024-01-30 Cornell University Dipeptides as inhibitors of human immunoproteasomes
EP3139930B1 (en) 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
AU2015264272A1 (en) 2014-05-20 2016-11-24 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
JP6700203B2 (ja) * 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
JP6758282B2 (ja) 2014-08-18 2020-09-23 コーネル・ユニバーシティーCornell University ヒト免疫プロテアソーム阻害剤としてのジペプチド模倣薬
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2905008T3 (es) 2015-10-15 2022-04-06 Univ Cornell Inhibidores de proteasomas y usos de los mismos
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
US11596629B2 (en) 2017-02-28 2023-03-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
IL273551B2 (en) 2017-10-11 2024-02-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis
EP3694605A4 (en) 2017-10-11 2021-10-27 Cornell University PEPTIDOMIMETIC PROTEASOME INHIBITORS
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
ES2196547T3 (es) 1997-02-15 2003-12-16 Millennium Pharm Inc Tratamiento de infartos por inhibicion de nf-kappab.
AU9580098A (en) 1997-09-25 1999-04-12 Millennium Pharmaceuticals, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
WO1999030707A1 (en) 1997-12-16 1999-06-24 Cephalon Inc. Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
HU230698B1 (hu) 2000-02-29 2017-09-28 Bristol-Myers Squibb Holdings Ireland Alacsony dózisú entecavir formuláció és alkalmazása
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
ES2702732T3 (es) 2001-01-25 2019-03-05 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
WO2003033507A1 (fr) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
PE20050360A1 (es) * 2003-08-14 2005-06-10 Cephalon Inc Inhibidores del proteasoma
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2005230930B2 (en) 2004-03-30 2011-09-29 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
CA2613795A1 (en) 2005-07-05 2007-01-11 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
GEP20125599B (en) 2007-08-06 2012-08-10 Millennium Pharm Inc Proteasome inhibitors
WO2009154737A1 (en) 2008-06-17 2009-12-23 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
PE20130383A1 (es) 2010-03-31 2013-04-24 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico

Also Published As

Publication number Publication date
EP2552216A4 (en) 2013-07-31
SG184222A1 (en) 2012-10-30
MX2012011298A (es) 2012-11-06
CA2794334A1 (en) 2011-10-06
RU2012146101A (ru) 2014-05-10
CN107266485A (zh) 2017-10-20
CL2012002733A1 (es) 2013-01-25
US9023832B2 (en) 2015-05-05
US8513218B2 (en) 2013-08-20
AR080863A1 (es) 2012-05-16
DOP2012000257A (es) 2012-11-15
UA110612C2 (uk) 2016-01-25
US20110245203A1 (en) 2011-10-06
UY33314A (es) 2011-10-31
CR20120529A (es) 2013-01-11
CN106008570A (zh) 2016-10-12
CN102892291A (zh) 2013-01-23
ZA201308086B (en) 2015-03-25
EP2552216B1 (en) 2018-01-24
EA201290980A1 (ru) 2013-03-29
MA34169B1 (fr) 2013-04-03
EA029521B1 (ru) 2018-04-30
NZ602622A (en) 2015-01-30
WO2011123502A1 (en) 2011-10-06
ZA201207406B (en) 2014-01-29
JP5933523B2 (ja) 2016-06-08
ECSP12012249A (es) 2012-11-30
US20140011998A1 (en) 2014-01-09
AU2011235227B2 (en) 2016-09-08
PE20130383A1 (es) 2013-04-24
KR20130036228A (ko) 2013-04-11
CA2794334C (en) 2018-06-12
JP2013523760A (ja) 2013-06-17
TN2012000465A1 (en) 2014-01-30
EP2552216A1 (en) 2013-02-06
AU2011235227A1 (en) 2012-10-18
US20140179631A1 (en) 2014-06-26
US8703743B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
ECSP10010015A (es) Inhibidores de proteasoma
CR20160014A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
PE20151067A1 (es) Inhibidores de autotaxina
CR20150045A (es) Inhibidores de hepatitis c
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
ECSP13013074A (es) Nuevos derivados de piridina
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CR20150204A (es) Nuevos derivados de piridina
CR20140553A (es) Compuestos de fenoxietil piperidina
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
AR090830A1 (es) Cocristales de metalaxil y protioconazol y procedimientos para la fabricacion y el uso de los mismos
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
DOP2010000027A (es) Inhibidores de proteasoma

Legal Events

Date Code Title Description
FG Application granted